Quantcast

Latest cancer therapies Stories

2009-03-18 06:00:00

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab...

2009-03-02 15:00:00

Annual Royalty Revenue Increases 72% from Prior Year DUBLIN, Calif., March 2 /PRNewswire-FirstCall/ -- SuperGen Inc., (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2008. The Company reported a net loss for the 2008 fourth quarter of $2.6 million, or $0.04 per share, compared with net income of $5.1 million, or $0.09 per share, for the same...

2009-02-24 06:00:00

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet. "I am excited to continue to contribute...

2009-02-19 07:24:00

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Fourth International Symposium on Regional Cancer Therapies, to be held February 21-23, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr. Pingpank, Adjunct Principal...

2009-02-19 06:00:00

PRINCETON, N.J., Feb. 19 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced a $55 million Series C financing. The financing was led by Zoticon Bioventures, a global drug development and healthcare investment firm. The company will use the funding to complete the pivotal Phase III clinical development program for its lead product candidate, Myocet(TM). Myocet is a liposomal...

2009-02-05 06:00:00

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, today announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the January 1 issue of Clinical Cancer Research. The study was supported by a grant from Roche and was conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). The study results suggest that...

2009-01-26 07:00:00

Rapid Identification and Optimization of Novel Drug Candidates using CLIMB(TM) DUBLIN, Calif., Jan. 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its Chief Science Officer, Dr. David Bearss, will participate in the symposium, "Accelerating Drug Development with Innovative Discovery Platforms." The event will take place on Tuesday, January 27, 2009 from 1:00 p.m....

2008-12-08 07:00:00

DUBLIN, Calif., Dec. 8 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). This research was presented at the 50th Annual Meeting of the American Society of Hematology. In a poster presentation entitled "Inhibiting...

2008-12-01 07:00:00

TSX: BMR TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it has been granted European Patent, # 1351713, entitled "Anti-Tenascin Monoclonal Antibody Therapy For Lymphoma." The claims cover the use of the Company's lead product for Glioblastoma, 131-Iodine (131I) Neuradiab(TM) candidate (monoclonal antibody 81C6), which binds to tenascin for the...

2008-11-05 15:00:09

TORONTO, Nov. 5 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it is participating in a GBM (glioblastoma multiforme) Awareness Day as a co-host with Voices Against Brain Cancer. The event will take place on Wednesday, November 12, 2008, at the Four Seasons Hotel in New York City. The panel discussion will begin at 4:15pm ET. Dr. Alan M. Ezrin, President and...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.